Alcon (SIX/NYSE: ALC), the global leader in eye care, announced today its acquisition of a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies for treating eye diseases.
The move aims to advance Aurion’s promising allogeneic cell therapy asset, AURN001, into Phase 3 trials for corneal edema secondary to corneal endothelial disease later this year.
Aurion will remain an independent entity, benefiting from Alcon’s extensive resources, including its R&D, regulatory, medical ophthalmic, and commercial expertise. In conjunction with the acquisition, Aurion has appointed former Chief Scientific Officer Dr. Arnaud Lacoste as CEO, effective immediately.
“Alcon is committed to addressing unmet needs in eye care, especially corneal endothelial disease, which impacts millions worldwide,” said David Endicott, CEO of Alcon. “Aurion’s innovative cell therapy aligns with our strategy to expand our pharmaceutical portfolio. The shortage of corneal tissue globally underscores the significance of this technology.”
Aurion’s AURN001 has garnered Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation from the U.S. FDA. The investigational therapy, comprising allogeneic human corneal endothelial cells and a rho kinase inhibitor, is yet to receive FDA approval.
Dr. Lacoste expressed confidence in the partnership, emphasizing Aurion’s ability to produce up to 1,000 doses from a single donor through manufacturing innovations. “Alcon’s global resources will enhance our mission to bring this vital therapy to patients,” Lacoste noted.
Aurion recently concluded a Phase 1/2 clinical trial for AURN001, enrolling 97 patients across U.S. and Canadian sites. The results support its transition to Phase 3 development. In Japan, Aurion launched Vyznova™, its first commercial product, in 2024 for bullous keratopathy, a debilitating corneal condition.
Alcon’s strategic acquisition marks a significant milestone in ophthalmology, paving the way for advancements in cell therapy and addressing critical needs in patient care.